Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Evaluation of Aristolochia indica L. and Piper nigrum L. methanol extract against centipede Scolopendra moristans L. using Wistar albino rats and screening of bioactive compounds by high pressure liquid chromatography: a polyherbal formulation.

Sivaraj D, Shanmugam S, Rajan M, Sasidharan SP, Sathyanarayanan S, Muniyandi K, Thangaraj P, de Souza Araújo AA.

Biomed Pharmacother. 2018 Jan;97:1603-1612. doi: 10.1016/j.biopha.2017.11.114. Epub 2017 Nov 28.

PMID:
29793322
2.

Phytochemical composition, antioxidant and anti-bacterial activity of Syzygium calophyllifolium Walp. fruit.

Sathyanarayanan S, Chandran R, Thankarajan S, Abrahamse H, Thangaraj P.

J Food Sci Technol. 2018 Jan;55(1):341-350. doi: 10.1007/s13197-017-2944-6. Epub 2017 Oct 30.

3.

Chemical profiling of Pterolobium hexapetalum leaves by HPLC analysis and its productive wound healing activities in rats.

Sathyanarayanan S, Muniyandi K, George E, Sivaraj D, Sasidharan SP, Thangaraj P.

Biomed Pharmacother. 2017 Nov;95:287-297. doi: 10.1016/j.biopha.2017.08.062. Epub 2017 Sep 12.

PMID:
28850928
4.

Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors.

Bregar A, Deshpande A, Grange C, Zi T, Stall J, Hirsch H, Reeves J, Sathyanarayanan S, Growdon WB, Rueda BR.

Gynecol Oncol. 2017 Jun;145(3):446-452. doi: 10.1016/j.ygyno.2017.03.006. Epub 2017 Mar 25.

5.

Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer.

Becker MA, Hou X, Tienchaianada P, Haines BB, Harrington SC, Weroha SJ, Sathyanarayanan S, Haluska P.

BMC Cancer. 2016 Oct 20;16(1):814.

6.

Development of a High-Throughput Gene Expression Screen for Modulators of RAS-MAPK Signaling in a Mutant RAS Cellular Context.

Severyn B, Nguyen T, Altman MD, Li L, Nagashima K, Naumov GN, Sathyanarayanan S, Cook E, Morris E, Ferrer M, Arthur B, Benita Y, Watters J, Loboda A, Hermes J, Gilliland DG, Cleary MA, Carroll PM, Strack P, Tudor M, Andersen JN.

J Biomol Screen. 2016 Oct;21(9):989-97. doi: 10.1177/1087057116658646. Epub 2016 Jul 26.

PMID:
27461835
7.

Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial.

Moran T, Felip E, Keedy V, Borghaei H, Shepherd FA, Insa A, Brown H, Fitzgerald T, Sathyanarayanan S, Reilly JF, Mauro D, Hsu K, Yan L, Johnson DH.

Exp Hematol Oncol. 2014 Nov 7;3(1):26. doi: 10.1186/2162-3619-3-26. eCollection 2014.

8.

Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical trial.

Di Cosimo S, Sathyanarayanan S, Bendell JC, Cervantes A, Stein MN, Braña I, Roda D, Haines BB, Zhang T, Winter CG, Jha S, Xu Y, Frazier J, Klinghoffer RA, Leighton-Swayze A, Song Y, Ebbinghaus S, Baselga J.

Clin Cancer Res. 2015 Jan 1;21(1):49-59. doi: 10.1158/1078-0432.CCR-14-0940. Epub 2014 Oct 15.

9.

Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.

Stoeck A, Lejnine S, Truong A, Pan L, Wang H, Zang C, Yuan J, Ware C, MacLean J, Garrett-Engele PW, Kluk M, Laskey J, Haines BB, Moskaluk C, Zawel L, Fawell S, Gilliland G, Zhang T, Kremer BE, Knoechel B, Bernstein BE, Pear WS, Liu XS, Aster JC, Sathyanarayanan S.

Cancer Discov. 2014 Oct;4(10):1154-67. doi: 10.1158/2159-8290.CD-13-0830. Epub 2014 Aug 7.

10.

Inhibition of notch signaling in combination with Paclitaxel reduces platinum-resistant ovarian tumor growth.

Groeneweg JW, DiGloria CM, Yuan J, Richardson WS, Growdon WB, Sathyanarayanan S, Foster R, Rueda BR.

Front Oncol. 2014 Jul 7;4:171. doi: 10.3389/fonc.2014.00171. eCollection 2014.

11.

Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors.

Zhang W, Haines BB, Efferson C, Zhu J, Ware C, Kunii K, Tammam J, Angagaw M, Hinton MC, Keilhack H, Paweletz CP, Zhang T, Winter C, Sathyanarayanan S, Cheng J, Zawel L, Fawell S, Gilliland G, Majumder PK.

Transl Oncol. 2012 Dec;5(6):422-9. Epub 2012 Dec 1.

12.

Multilevel analysis of the physical health perception of employees: community and individual factors.

Sathyanarayanan S, Brooks AJ, Hagen SE, Edington DW.

Am J Health Promot. 2012 May-Jun;26(5):e126-36. doi: 10.4278/ajhp.110316-QUAL-120.

PMID:
22548431
13.

Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor.

Nagashima K, Shumway SD, Sathyanarayanan S, Chen AH, Dolinski B, Xu Y, Keilhack H, Nguyen T, Wiznerowicz M, Li L, Lutterbach BA, Chi A, Paweletz C, Allison T, Yan Y, Munshi SK, Klippel A, Kraus M, Bobkova EV, Deshmukh S, Xu Z, Mueller U, Szewczak AA, Pan BS, Richon V, Pollock R, Blume-Jensen P, Northrup A, Andersen JN.

J Biol Chem. 2011 Feb 25;286(8):6433-48. doi: 10.1074/jbc.M110.156463. Epub 2010 Nov 30.

14.

Presenteeism: critical issues.

Brooks A, Hagen SE, Sathyanarayanan S, Schultz AB, Edington DW.

J Occup Environ Med. 2010 Nov;52(11):1055-67. doi: 10.1097/JOM.0b013e3181f475cc. Review.

PMID:
21063183
15.

Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors.

Andersen JN, Sathyanarayanan S, Di Bacco A, Chi A, Zhang T, Chen AH, Dolinski B, Kraus M, Roberts B, Arthur W, Klinghoffer RA, Gargano D, Li L, Feldman I, Lynch B, Rush J, Hendrickson RC, Blume-Jensen P, Paweletz CP.

Sci Transl Med. 2010 Aug 4;2(43):43ra55. doi: 10.1126/scitranslmed.3001065.

16.

Identification of novel genes involved in light-dependent CRY degradation through a genome-wide RNAi screen.

Sathyanarayanan S, Zheng X, Kumar S, Chen CH, Chen D, Hay B, Sehgal A.

Genes Dev. 2008 Jun 1;22(11):1522-33. doi: 10.1101/gad.1652308.

17.

Molecular analysis of sleep: wake cycles in Drosophila.

Sehgal A, Joiner W, Crocker A, Koh K, Sathyanarayanan S, Fang Y, Wu M, Williams JA, Zheng X.

Cold Spring Harb Symp Quant Biol. 2007;72:557-64. doi: 10.1101/sqb.2007.72.018. Review.

PMID:
18419315
18.

Post-translational regulation of the Drosophila circadian clock requires protein phosphatase 1 (PP1).

Fang Y, Sathyanarayanan S, Sehgal A.

Genes Dev. 2007 Jun 15;21(12):1506-18.

19.

Interaction between sleep and the immune response in Drosophila: a role for the NFkappaB relish.

Williams JA, Sathyanarayanan S, Hendricks JC, Sehgal A.

Sleep. 2007 Apr;30(4):389-400.

20.

Chronic depletion of glutathione (GSH) and minimal modification of LDL in vivo: its prevention by glutathione mono ester (GME) therapy.

Rajasekaran NS, Sathyanarayanan S, Devaraj NS, Devaraj H.

Biochim Biophys Acta. 2005 Jun 30;1741(1-2):103-12. Epub 2004 Dec 15.

21.

Mouse HSF1 disruption perturbs redox state and increases mitochondrial oxidative stress in kidney.

Yan LJ, Rajasekaran NS, Sathyanarayanan S, Benjamin IJ.

Antioxid Redox Signal. 2005 Mar-Apr;7(3-4):465-71.

PMID:
15706094
22.

Posttranslational regulation of Drosophila PERIOD protein by protein phosphatase 2A.

Sathyanarayanan S, Zheng X, Xiao R, Sehgal A.

Cell. 2004 Feb 20;116(4):603-15.

23.

Novel insights into the regulation of the timeless protein.

Ashmore LJ, Sathyanarayanan S, Silvestre DW, Emerson MM, Schotland P, Sehgal A.

J Neurosci. 2003 Aug 27;23(21):7810-9.

Supplemental Content

Loading ...
Support Center